The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer

Cancer Research

Volumn 59, Issue 23, 1999, Pages 5878-5881

  Febbo, Phillip G ^a   Kantoff, Philip W ^a   Platz, Elizabeth A ^d   Casey, Daniel ^a   Batter, Steve ^a   Giovannucci, Edward ^b,c   Hennekens, Charles H ^b,c   Stampfer, Meir J ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d Dana Farber Cancer Institute ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIOL DERIVATIVE; NUCLEOTIDE; STEROID 5ALPHA REDUCTASE; ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; BETA CAROTENE; ISOENZYME; LEUCINE; VALINE;

ADULT; AGED; CANCER RISK; CARCINOGENESIS; CAUCASIAN; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; AMINO ACID SUBSTITUTION; ARTICLE; GENETICS; HEART DISEASE; MIDDLE AGED; NEOPLASM; PROSTATE TUMOR; RISK FACTOR; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ANTICARCINOGENIC AGENTS; ASPIRIN; BETA CAROTENE; BOSTON; DOUBLE-BLIND METHOD; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEART DISEASES; HUMANS; ISOENZYMES; LEUCINE; MALE; MIDDLE AGED; NEOPLASMS; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK FACTORS; TESTOSTERONE 5-ALPHA-REDUCTASE; VALINE;

EID: 0033233173     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Ross, R., Coetzee, G., Reichardt, J., Skinner, E., and Henderson, B. Does the racial-ethnic variation in prostate cancer risk have a hormonal basis? Cancer (Phila.), 75: 1778-1782, 1995.
2. Jenkins, E. P., Andersson, S., Imperato-McGinley, J., Wilson, J. D., and Russel, D. W., Genetic and pharmacologic evidence for more than one human steroid 5α-reductase. J. Clin. Investig., 89: 293-300, 1992.
3. Ross, R., Bernstein, L., Lobo, R., Shimizu, H., Slanczyk, F., Pike, M., and Henderson, B. 5α-Reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet, 339: 887-889, 1992.
4. Thigpen, A., Davis, D., Milatovich, A., Mendonca, B., Imperato-McGinley, J., Griffin, J., Francke, U., Wilson, J., and Russell, D. Molecular genetics of steroid 5α-reductase 2 deficiency. J. Clin. Investig., 90: 799-809, 1992.
5. Andersson, S., Berman, D M., Jenkins, E. P., and Russell, D. W. Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature (Lond.), 354: 159-161, 1991.
6. Wilson, J. D., Griffin, J. E., and Russell, D. S. Steroid 5α-reductase 2 deficiency. Endocr. Rev., 14: 577-593, 1993.
7. Davis, D., and Russell, D., Unusual length polymorphism in human steroid 5α-reductase type 2 gene (SRD5A2). Hum. Mol. Genet., 2, 820, 1993.
8. Reichardt, J., Makridakis, N., Henderson, B., Yu, M., Pike, M., and Ross, R. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res., 55: 3973-3975, 1995.
9. Kantoff, P., Febbo, P., Giovannucci, E., Krithivas, K., Dahl, D., Chang, G., Hennekens, C., Brown, M., and Stampfer, M. A polymorphism of the 5α-reductase gene and its association with prostate cancer: A case-control analysis. Cancer Epidemiol. Biomark. Prev., 6: 189-192, 1997.
10. Makridakis, N., Ross, R., Pike, M., Chang, L., Stanczyk, F., Kolonel, L., Shi, C., Yu, M., Henderson, B., and Reichardt, J. A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res., 57: 1020-1022, 1997.
11. Ross, R., Pike, M., Coetzee, G., Reichardt, J., Yu, M., Feigelson, H., Stanczyk, F., Kolonel, L., and Henderson, B. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res., 58: 4497-4504, 1998.
12. Steering Committee of the Physicians' Health Study Preliminary Report: findings from the aspirin component of the ongoing Physician's Health Study. N. Engl. J. Med., 318: 262-254, 1988.
13. Steering Committee of the Physicians' Health Study Report: final report on the aspirin component of the ongoing Physicians' Health Study. N. Engl. J. Med., 321: 129-135, 1989.
14. Catalona, W., and Avioli, L., Diagnosis, staging, and surgical treatment of prostatic carcinoma. Arch. Intern. Med., 147: 361-363, 1987.
15. Gittes, R., Carcinoma of the prostate. N. Engl. J. Med., 324: 236-245, 1991.
16. Gann, P. H., Hennekens, C. H., Ma, J., Longcope, C., and Stampfer, M. J., Prospective study of sex hormone levels and risk of prostate cancer. J. Natl. Cancer Inst., 88: 1118-1126, 1995.
17. Rosner, B. Fundamentals of Biostatistics, Ed. 2, pp. 467-472. Boston: Duxbury Press, 1986.
18. Kleinbaum, D., Kupper, L., and Morganstern, H., Epidemiologic Research. Principles and Quantitative Methods, pp. 419-446. New York: Van Nostrand Reinhold, 1982.
19. Coffey, D., Physiological control of prostatic growth: an overview. Prostate cancer. Union Int. Contre Cancer Tech. Rep. Ser., 48: 4-23, 1979.
20. Pollard, M., Luckert, P. H., and Schmidt, M. A. Induction of prostate adenocarcinomas in Lobund Wistar rats by testosterone. Prostate, 3: 563-568, 1982.
21. Noble, R. L. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res., 37: 1929-1933, 1977.
22. Ross, R., Bernstein, L., Judd, H., Hanisch, R., Pike, M., and Henderson, B. Serum testosterone levels in healthy young black and white men. J. Natl. Cancer Inst., 76: 45-48, 1986.
23. Guess, H. A., Friedman, G. D., Sadler, M. C., Stanczyk, F. Z., Vogelman, J. H., Imperato-McGinley, J., Lobo, R. A., and Orentreich, N. 5α-Reductase activity and prostate cancer: a case-control study using stored sera. Cancer Epidemiol. Biomark. Prev., 6: 21-24, 1997.
24. Nomura, A. M., Stemmermann, G. N., Chyou, P-H., Henderson, B., and Stanczyk, F. Z., Serum androgens and prostate cancer. Cancer Epidemiol. Biomark. Prev., 5: 621-625, 1996.